Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.
Authors: Neoptolemos, J.P., Palmer, D., Greenhalf, W., Ghaneh, P., Jackson, R., Evans, A., Shaw, V., Wadsley, J., Valle, J.W., Wasan, H., Falk, S., Cunningham, D., Coxon, F.Y., Ross, P.J., Wadd, N., Hickish, T., Costello, E., Campbell, F., Rawcliffe, C., Middleton, G.W.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Publication Date: 20/05/2017
Volume: 35
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/JCO.2017.35.15_suppl.4104
Source: Web of Science